Sarah Pringle

Sarah Pringle is a senior reporter focused on M&A, private equity and auctions in the healthcare industry. Prior to joining The Deal, Pringle reported on U.S. and Canadian equity markets at Bloomberg News in New York and MarketWatch in San Francisco.

Recent Articles By The Author

Allergan Shares Rise on $2.5B Deal for Body-Sculptor Zeltiq

Allergan Shares Rise on $2.5B Deal for Body-Sculptor Zeltiq

Allergan is buying body-sculptor Zeltiq. CEO Brent Saunders deems it to be the Botox of 10 years ago and he expects the deal to be immediately accretive.

Cigna Is Ready for a Dealmaking Spree If and When Anthem Deal Is Officially Killed

Cigna Is Ready for a Dealmaking Spree If and When Anthem Deal Is Officially Killed

CEO David Cordani said the company has up to $14 billion to put to work for potential transactions, if its $44 billion deal with Anthem is not finalized.

Allergan's Fourth-Quarter Comments Should Comfort Investors

Allergan's Fourth-Quarter Comments Should Comfort Investors

The company has seemingly reset expectations and is viewed as having an in-development pipeline that covers multiple potential catalysts.

Allergan Followers Optimistic Ahead of Wednesday's Fourth-Quarter Report

Allergan Followers Optimistic Ahead of Wednesday's Fourth-Quarter Report

Investors await more detail around the drugmaker's full-year outlook, having fallen short of earnings expectations during its latest quarter.

Biotech Premarket Movers: PharmAthene, Earth Science Tech, Pulmatrix

Biotech Premarket Movers: PharmAthene, Earth Science Tech, Pulmatrix

PharmAthene shares spiked premarket Tuesday premarket, adding to the massive gains seen a day earlier.